Skip to content

Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock

Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock: A Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03258684
Acronym
HYVCTTSSS
Enrollment
80
Registered
2017-08-23
Start date
2017-09-25
Completion date
2019-02-02
Last updated
2019-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

corticosteroid, hydrocortisone, septic shock, thiamine, vitamin C

Brief summary

In this prospective clinical study, the investigators compare the outcome and clinical course of consecutive septic participants treated with intravenous vitamin C, hydrocortisone, and thiamine (treatment group) with a control group treated in the investigators' ICU. The primary outcome is hospital survival. A propensity score is generated to adjust the primary outcome.There is 70 participants in each group.

Detailed description

A prospective randomized controlled trial is conducted.One hundred and forty severe sepsis or septic shock participants admit to the Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University from September 2017.The participants are divided into control group ( n = 70 ) and treatment group ( n = 70 ).The participants in both groups are treated according to 2016 international guidelines for management of sepsis and septic shock,and the participants in treatment group receive intravenous vitamin C, hydrocortisone, and thiamine. The participants in control group receive normal saline.The patients' clinical and demographic data, including age, sex, admitting diagnosis, comorbidities, requirement for mechanical ventilation, use of vasopressors, daily urine output, fluid balance after 24 and 72 h, length of ICU stay (LOS),and laboratory data (serum creatinine, White Blood Cell (WBC), platelet count, total bilirubin, procalcitonin(PCT), and lactate levels), are recorded.The primary outcome is hospital survival. Secondary outcomes include duration of vasopressor therapy,requirement for renal replacement therapy in patients with Acute kidney injury (AKI), ICU LOS, and the change in serum procalcitonin and Sepsis-Related Organ Failure Assessment (SOFA score) over the first 72 h. Summary statistics are used to describe the clinical data and are presented as means±SD, medians and interquartile range, or percentages as appropriate.Statistical analysis is performed with NCSS 11 (NCSS Statistical Software) and SPSS Statistics version 24 (IBM).

Interventions

DRUGHydrocortisone, Vitamin C, and Thiamine

Intervention

OTHERNormal saline

Placebo

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

The participants in treatment group receive intravenous vitamin C, hydrocortisone, and thiamine. The participants in control group receive normal saline.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A primary diagnosis of sepsis or septic shock (the diagnoses of sepsis and septic shock are based on the 2016 the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) and a procalcitonin (PCT) level≥2ng/mL. Sepsis: Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock: Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality.

Exclusion criteria

* Patients \< 18 years of age, pregnant patients, and patients with limitations of care.

Design outcomes

Primary

MeasureTime frame
hospital survivalUp to Day 14

Secondary

MeasureTime frame
duration of vasopressor therapyUp to hour 72
requirement for renal replacement therapy in participants with Acute kidney injury(AKI)Up to Day 14
ICU length of stay(LOS)Up to Day 14
the change in serum procalcitonin (PCT)Up to hour 72
Sepsis-Related Organ Failure Assessment(SOFA)scoreUp to hour 96

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026